FindTrial
Sign In

L-dopa

DRUG15 trials

Sponsors

Merck Sharp & Dohme LLC, The University of Texas Health Science Center, Houston, University Hospital, Toulouse, UCB Pharma, MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Conditions

AkinesiaAlcohol DependenceBrain DiseasesCentral Nervous System DiseasesCocaine AbuseCocaine DependenceCognitive DeclineDelayed Levodopa Onset

Phase 1

Pharmacological Modulation of Belief Salience
CompletedNCT03754062
King's College LondonHaloperidol, L-DOPA, Placebo
Start: 2017-06-01End: 2019-09-01Updated: 2019-10-10

Phase 2

Dyskinesia in Parkinson's Disease (Study P04501)
CompletedNCT00406029
Merck Sharp & Dohme LLCBrain Diseases, Central Nervous System Diseases, Movement Disorders +2
Start: 2006-11-20End: 2008-11-03Updated: 2018-11-09
Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
CompletedNCT00537017
Merck Sharp & Dohme LLCBrain Diseases, Central Nervous System Diseases, Movement Disorders +2
Start: 2007-11-23End: 2009-11-19Updated: 2021-02-02
L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease
NCT02347059
University of TorontoParkinson's Disease
Start: 2015-01-31End: 2016-08-31Target: 40Updated: 2015-01-27
Effects of 5HTP and LDOPA on CNS Excitability After SCI
SuspendedNCT04000919
Jessica M D'AmicoSpinal Cord Injuries
Start: 2019-06-19End: 2023-12-30Target: 30Updated: 2022-10-17
Dopaminergic Dysfunction in Late-Life Depression
Active, not recruitingNCT04469959
Vanderbilt University Medical CenterCognitive Decline, Depressive Disorder, Treatment-Resistant, Gait Impairment +2
Start: 2021-02-15End: 2026-07-30Target: 100Updated: 2026-02-06
Improving Therapeutic Learning for PTSD
NCT04558112
University of Wisconsin, MadisonPost Traumatic Stress Disorder, PTSD
Start: 2021-02-18End: 2023-12-31Target: 120Updated: 2023-08-30
Etoricoxib in Patients With Parkinsonian Disease
Not yet recruitingNCT07370532
Ihab Elsayed HassanParkinson Disease
Start: 2026-06-30End: 2027-11-20Target: 60Updated: 2026-01-27

Phase 3

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
CompletedNCT01504178
University Hospital, ToulouseParkinson's Disease
Start: 2011-05-31End: 2015-12-31Updated: 2017-02-23
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
CompletedNCT01646255
UCB PharmaIdiopathic Parkinson's Disease
Start: 2012-07-31End: 2014-10-31Updated: 2018-04-04

Phase 4

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
CompletedNCT01770145
MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsAkinesia, Delayed Levodopa Onset, Hypomobility +2
Start: 2012-12-31End: 2014-04-30Updated: 2023-08-14
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
TerminatedNCT03761030
New York State Psychiatric InstituteDepression, Dysthymia, Major Depressive Disorder
Start: 2019-01-09End: 2021-09-08Updated: 2023-05-22

Unknown Phase

Substance Abuse Pre-Treatment Screening Study
RecruitingNCT00439049
The University of Texas Health Science Center, HoustonAlcohol Dependence, Cocaine Abuse, Cocaine Dependence +2
Start: 2005-10-31End: 2026-06-30Target: 7500Updated: 2023-12-20
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia
NCT02578849
Aarhus University HospitalParkinson´s Disease
Start: 2012-01-31End: 2016-01-31Target: 45Updated: 2015-10-19
Oxytocin and Dopamine's Effect on Vicarious Optimism
CompletedNCT03891095
Beijing Normal UniversityL-DOPA Group, Oxytocin Group, Placebo Group
Start: 2018-12-01End: 2019-01-16Updated: 2019-03-26

Related Papers

Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
2017-08-1019 citations
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
2011-03-01134 citations